Double maintains 3 strategies that include APLS - Apellis Pharmaceuticals, Inc.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CTA | -<0.01% | $1.06B | 0.76% |
| STIP | -0.01% | $12.72B | 0.03% |
| AGGH | 0.14% | $324.95M | 0.29% |
| OWNS | 0.19% | $129.31M | 0.3% |
| UNG | -0.31% | $360.54M | 1.06% |
| SCHR | 0.32% | $10.92B | 0.03% |
| IBTL | -0.33% | $381.01M | 0.07% |
| UGA | 0.33% | $72.33M | 0.97% |
| BNO | -0.36% | $103.79M | 1% |
| FXY | 0.42% | $816.38M | 0.4% |
| LMBS | 0.45% | $5.11B | 0.64% |
| UTEN | 0.46% | $210.24M | 0.15% |
| BOXX | -0.47% | $6.80B | 0.19% |
| USO | 0.50% | $1.13B | 0.6% |
| DBE | -0.57% | $52.20M | 0.77% |
| IBTO | 0.59% | $352.69M | 0.07% |
| JMST | -0.59% | $4.06B | 0.18% |
| WEAT | -0.61% | $117.15M | 0.28% |
| TYA | 0.66% | $152.69M | 0.15% |
| IBTK | -0.66% | $448.89M | 0.07% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 55.98% | $4.82B | 0.35% |
| IBB | 51.87% | $5.26B | 0.45% |
| GNOM | 51.78% | $44.57M | 0.5% |
| PBE | 46.23% | $223.19M | 0.58% |
| ARKG | 45.13% | $1.02B | 0.75% |
| IWO | 43.76% | $11.60B | 0.24% |
| BBH | 43.73% | $330.62M | 0.35% |
| IWC | 43.72% | $818.14M | 0.6% |
| IWM | 43.19% | $63.72B | 0.19% |
| VTWO | 42.95% | $12.52B | 0.07% |
| PAWZ | 42.82% | $62.28M | 0.5% |
| KJUL | 42.71% | $119.50M | 0.79% |
| KJAN | 41.56% | $287.30M | 0.79% |
| PINK | 41.51% | $130.57M | 0.5% |
| SCHA | 41.20% | $17.26B | 0.04% |
| IWN | 40.91% | $10.96B | 0.24% |
| ESML | 40.61% | $1.84B | 0.17% |
| QQQJ | 40.51% | $621.52M | 0.15% |
| PRFZ | 40.42% | $2.36B | 0.34% |
| GSSC | 40.34% | $561.54M | 0.2% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| K | -11.39% | $27.76B | +41.17% | 2.85% |
| LITB | -10.31% | $21.24M | -78.57% | 0.00% |
| VSA | -9.94% | $8.67M | -19.04% | 0.00% |
| CORT | -9.45% | $7.57B | +133.90% | 0.00% |
| HUSA | -7.88% | $19.66M | -19.53% | 0.00% |
| MCK | -6.79% | $88.11B | +20.93% | 0.40% |
| RPRX | -6.11% | $15.25B | +39.62% | 2.38% |
| PULM | -6.10% | $25.57M | +219.63% | 0.00% |
| ED | -5.79% | $36.00B | +12.64% | 3.34% |
| MO | -5.45% | $99.67B | +28.77% | 6.90% |
| FATBB | -4.66% | $49.01M | -5.66% | 10.18% |
| AEP | -4.58% | $55.16B | +17.93% | 3.54% |
| NEUE | -3.62% | $61.24M | +29.92% | 0.00% |
| EXC | -3.43% | $43.33B | +23.58% | 3.62% |
| CBOE | -3.20% | $24.23B | +35.36% | 1.09% |
| CEG | -2.16% | $96.10B | +45.97% | 0.48% |
| CYCN | -2.08% | $10.59M | +46.35% | 0.00% |
| CCEC | -2.03% | $1.02B | +3.91% | 2.58% |
| ZCMD | -2.01% | $29.55M | -8.59% | 0.00% |
| PPC | -1.68% | $10.84B | +33.46% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| COR | -0.13% | $56.44B | +30.86% | 0.74% |
| CHRW | -0.18% | $11.77B | +13.29% | 2.48% |
| CME | 0.26% | $99.39B | +40.68% | 3.86% |
| BULL | 0.31% | $6.47B | +25.76% | 0.00% |
| OCFT | -0.46% | $267.49M | +332.74% | 0.00% |
| LMT | 0.48% | $108.37B | -0.75% | 2.81% |
| OXBR | 0.55% | $16.90M | +1.79% | 0.00% |
| VSTA | 0.74% | $344.07M | +39.29% | 0.00% |
| CIG.C | -0.75% | $2.65B | +29.61% | 0.00% |
| LFVN | -0.80% | $168.68M | +123.71% | 1.22% |
| IMNN | 0.84% | $16.26M | -34.16% | 0.00% |
| FROG | 0.85% | $4.74B | +15.86% | 0.00% |
| DFDV | 0.95% | $300.56M | +2,130.16% | 0.00% |
| SAVA | 0.98% | $97.10M | -81.34% | 0.00% |
| PARAA | 1.07% | $15.57B | +14.88% | 0.87% |
| ANGI | 1.08% | $785.07M | -11.57% | 0.00% |
| KR | -1.17% | $46.43B | +38.38% | 1.85% |
| VHC | 1.20% | $48.19M | +108.24% | 0.00% |
| STG | -1.35% | $30.78M | -22.51% | 0.00% |
| ARLP | 1.37% | $3.42B | +6.48% | 10.66% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -32.34% | $164.54M | 0.85% |
| BTAL | -30.37% | $296.22M | 1.43% |
| TAIL | -30.36% | $99.63M | 0.59% |
| CLIP | -15.32% | $1.51B | 0.07% |
| ULST | -15.17% | $654.75M | 0.2% |
| USDU | -13.94% | $162.43M | 0.5% |
| PSQA | -11.59% | $35.44M | 0.2% |
| XHLF | -11.28% | $1.73B | 0.03% |
| IVOL | -10.89% | $347.03M | 1.02% |
| LDUR | -10.36% | $929.65M | 0.5% |
| XONE | -10.21% | $625.28M | 0.03% |
| FTSD | -8.73% | $231.81M | 0.25% |
| SPTS | -8.41% | $5.80B | 0.03% |
| UUP | -8.18% | $201.63M | 0.77% |
| UTWO | -7.38% | $379.52M | 0.15% |
| BUXX | -6.92% | $315.18M | 0.25% |
| SHYM | -6.04% | $357.13M | 0.35% |
| IBTG | -6.02% | $1.92B | 0.07% |
| VGSH | -5.75% | $22.80B | 0.03% |
| GBIL | -5.29% | $6.37B | 0.12% |
Yahoo
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, analyst Judah Frommer from Morgan Stanley raised the firm’s price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $26.00 from $25.00 while maintaining a Hold rating on the stock. Frommer attributed the rating to […]
Yahoo
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is among the best growth stocks to invest in for the next 5 years. The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O. Watson, sold 5,000 shares of common stock for $18.77, higher than the current trading price of $17.62. This transaction, worth $93,850, although it follows a challenging period, […]
Yahoo
Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone payments dependent on regulatory approvals in the European Union for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Yahoo
Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGNNon-dilutive financing further strengthens Apellis’ balance sheet Apellis retains full U.S. commercialization rights for systemic pegcetacoplanTransaction underscores shared confidence in the meaningful growth potential in rare kidney diseases WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase
SeekingAlpha
Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why BEAM stock is a Strong Buy.
Yahoo
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ROIV | 46.72% | $7.46B | +4.68% | 0.00% |
| BPMC | 44.24% | $8.29B | +17.58% | 0.00% |
| ARWR | 44.22% | $2.33B | -32.59% | 0.00% |
| KYMR | 44.02% | $3.12B | +47.65% | 0.00% |
| DNLI | 43.93% | $2.16B | -30.05% | 0.00% |
| IMVT | 43.91% | $2.87B | -35.84% | 0.00% |
| DAWN | 43.48% | $682.17M | -50.15% | 0.00% |
| RARE | 43.01% | $3.73B | -1.87% | 0.00% |
| COGT | 42.88% | $843.67M | -11.36% | 0.00% |
| EYPT | 42.47% | $664.72M | +12.07% | 0.00% |
| BEAM | 41.87% | $2.00B | -15.33% | 0.00% |
| CLDX | 40.59% | $1.47B | -38.43% | 0.00% |
| CRNX | 40.22% | $2.76B | -33.39% | 0.00% |
| IGMS | 40.15% | $79.35M | -79.53% | 0.00% |
| NTLA | 39.83% | $1.11B | -53.25% | 0.00% |
| CYTK | 39.36% | $4.10B | -36.84% | 0.00% |
| IDYA | 39.14% | $1.92B | -34.15% | 0.00% |
| RGNX | 39.03% | $434.35M | -20.33% | 0.00% |
| PAX | 39.00% | $2.26B | +14.95% | 4.16% |
| OCUL | 38.98% | $1.51B | +41.41% | 0.00% |
Current Value
$18.001 Year Return
Current Value
$18.001 Year Return
